Canadian Medical Association Journal · 2004 · 21 citations · 9 references
PharmacyPharmaceutical PolicyDrug Approval ProcessesPharmaceutical RegulationRelease Of InformationDrug ApprovalMarket Authorization ProceduresDrug Approval PolicyDrug Information PolicyFda Drug RegulationMarket Authorization ProcessesPost-approval Drug Safety
In Canada, the information used to approve new drugs is deemed commercially sensitive and hence confidential under the Access to Information Act,[1][1] and the Therapeutic Products Directorate (TPD) will not release such information without the manufacturer's approval. As a consequence, safety and
9